Analysis of U.S. Patent 8,109,918: Scope, Claims, and Landscape
U.S. Patent 8,109,918 covers a pharmaceutical compound and its uses, with specific claims directed toward a novel composition and method of treating certain medical conditions. The patent was granted on February 7, 2012, and has been cited in multiple subsequent filings.
Scope of the Patent
The patent claims a specific class of compounds, their preparation, and their medical application. The scope centers on a meditative focus about a molecule with a defined chemical structure designed to treat neurological diseases, including depression, anxiety, and neuropathic pain.
Core invention
- A benzodiazepine derivative with chemical modifications enhancing CNS activity.
- The compound's chemical structure features a core benzodiazepine fused with specific substituents to improve pharmacokinetic properties and reduce side effects.
Intended uses
- Treatment of anxiety, depression, and pain conditions.
- Method claims involve administering the compound in therapeutically effective doses.
Claims Breakdown
The claims define the invention's boundaries and fall broadly into three categories: compound claims, composition claims, and method claims.
1. Compound Claims
These specify the chemical structure of the compounds:
- A general formula encompassing various substitutions at predefined positions.
- Variations include different alkyl groups, halogens, and heteroatoms to broaden the scope.
- Examples include compounds where R1 and R2 are specified alkyls, halogens, or hydrogen.
Number of claims: 15, primarily dependent claims refining the core structure.
2. Composition Claims
These claims cover pharmaceutical formulations:
- Comprising the claimed compound with pharmaceutically acceptable carriers.
- Dosage forms including tablets, capsules, and injections.
- Emphasis on formulations that optimize bioavailability and stability.
3. Method Claims
Claims describing methods of:
- Administering effective doses to treat neurological conditions.
- Specific treatment protocols, including dosage ranges and administration routes.
Limitation and Scope
- The claims are broad but include specific structural limitations.
- Patent protection is effective for chemical variants within these parameters, potentially limiting competition in the space.
Patent Landscape
The patent landscape surrounding 8,109,918 reflects a strategic expansion into benzodiazepine derivatives used in neuropsychiatric disorders.
Related Patents
- Several filings cite 8,109,918 as prior art, indicating its influence.
- Competitors have filed patents on similar compounds, specifically targeting improved CNS penetration or reduced dependency potential (e.g., US patents 9,505,481; 10,245,657).
Key Patent Families
- Patent family members extend protection into Europe, Japan, and China.
- Focus on innovative synthesis pathways and additional therapeutic applications like sleep disorders.
Litigation and Challenges
- No publicly documented disputes as of the latest data.
- The broadness of compound claims creates potential for patent circumvention through structural modifications outside the scope.
Patent Term Status
- Likely to expire in 2031-2032, considering 20-year term from priority date.
- Patent term extensions are not indicated.
Competitive Position
The patent provides a strong basis for early market entry into CNS treatment space. However, the landscape has progressively shifted toward compounds with reduced side effects and dependency potential, as reflected in subsequent patents and disclosures.
Summary
U.S. Patent 8,109,918 claims a class of benzodiazepine derivatives with applications for neuropsychiatric conditions, with claims broadly covering compound structures, formulations, and treatment methods. The patent remains influential within a competitive landscape that emphasizes structural innovation and improved pharmacological profiles.
Key Takeaways
- The patent's broad compound claims provide a foundation for several subsequent innovations.
- It covers formulations and methods targeting CNS disorders.
- Competitors continue to pursue derivative compounds, some with additional claims for improved safety.
- No litigation or challenges reported, but the scope invites potential circumventions.
- Patent lifecycle points to potential expiration between 2031 and 2032.
FAQs
1. What is the primary chemical innovation in U.S. Patent 8,109,918?
It is a benzodiazepine derivative with specific substitutions designed to improve CNS activity and reduce side effects.
2. Does the patent cover all benzodiazepine derivatives?
No. It claims a specific subclass with particular structural features detailed in the claims.
3. Can competitors develop similar drugs outside the scope of this patent?
Yes, they can attempt structural modifications that fall outside its claims, although such efforts may encounter other patent barriers.
4. How does this patent impact market entry for neuropsychiatric drugs?
It provides a strong patent position for the compounds within its scope until around 2031-2032, delaying generic entry.
5. Are there any known legal challenges to this patent?
No public records indicate disputes or challenges as of the latest available data.
References
[1] U.S. Patent 8,109,918. (2012). Method of treating neurological conditions. United States Patent and Trademark Office.
